Seattle Genetics (SGEN +2.1%) erases a +5% loss at the open, despite posting a Q1 revenue miss...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

Seattle Genetics (SGEN +2.1%) erases a +5% loss at the open, despite posting a Q1 revenue miss late yesterday. Total revenue actually jumped nearly 300% Y/Y, driven by higher sales of its lymphoma drug Adcetris. RBC Capital says the company still has multiple market expansion opportunities, and should be bought on weakness.